** Shares of clinical-stage biopharmaceutical firm Radiopharm Theranostics RAD.AX rise as much as 21.7% to A$0.028, their highest since Dec. 16
** Co inks co-development deal to develop biopharmaceuticals with Massachusetts-based Lantheus LNTH.O in Australia
** Deal includes basket clinical trial targeting multiple solid tumours
** Co to receive up to $2 mln in milestone payments upon achieving key objectives, with the LNTH footing all costs
** Including session's moves, stock trims YTD losses to 64.9% as of 2340 GMT
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。